CD55 is expressed as a 60-70 kD single chain Glycosylphosphatidylinositol (GPI) anchored glycoprotein (in erythrocytes). In other cells the molecular weight is somewhat larger. It is comprised of four N-terminal short consensus repeats (SCR) modules (4 Cys in 1-3,2-4 linkage) with C3b/C4b binding and regulator activity in SCR 2,3,4. CD55 is often involved in the protection of cells from autologous compliment-mediated injury and are partially or completely lacking in peripheral blood cells. CD55 inhibits the formation and accelerates the decay of C3/C5 convertase complexes both of classical and alternative pathway [1]. CD55 sets a protective barrier threshold against inappropriate complement activation and deposition on plasma membranes, especially by the classical pathway of complement activation, by limiting formation and half-life of the C3 convertases. Since CD55 is well known membrane-associated complement regulator protein, like CD59, and present on all blood cells, anti-CD55 and anti-CD59 appear to be the most effective Mabs to detect very minor negative cell subsets (less than 1 % on erythrocytes or less than 5 % on PMN leukocytes.Synonyms: Complement decay-accelerating factor